New Approach Methodologies (NAMs) are transforming the way drugs, medical products, and chemicals are evaluated by providing more predictive, human-relevant, and sustainable alternatives to traditional testing approaches. By integrating advanced in vitro models, computational tools, artificial intelligence, in silico toxicology, and innovative preclinical strategies, NAMs offer new opportunities to improve safety assessment, reduce development timelines, lower costs, and support regulatory decision-making.
This round table will bring together leading experts from industry and technology providers to explore the current state and future potential of NAMs across the life sciences sector. The discussion will examine how emerging methodologies are being implemented in research and development workflows, the scientific and regulatory challenges that remain, and the collaborative efforts needed to accelerate adoption.
Representatives from
CMG MedDev,
ProtoQSAR,
Labcorp and IVT
Becytes will share their perspectives on the role of digital technologies, predictive modeling, advanced biological systems, and regulatory science in shaping the next generation of safety and efficacy assessment.
The session will address key questions including:
- How can NAMs improve the predictivity and translational value of preclinical testing?
- What role do AI, computational toxicology, and in silico approaches play in modern risk assessment?
- How are regulators responding to the growing adoption of NAMs?
- What barriers are limiting broader implementation, and how can they be overcome?
- How can collaboration between biotechnology companies, technology developers, regulators, and investors accelerate the transition toward human-relevant innovation?
Attendees will gain practical insights into the opportunities and challenges associated with NAMs, as well as a forward-looking view of how these technologies are reshaping drug development, chemical safety assessment, and the broader bioeconomy.
Arosa I+D TBA
Kent Grindstaff, Consulting Director of Scientific Affairs (Kansas, USA), BeCytes Biotechnologies (BioIVT),
TBC
